Lexeo Therapeutics price target lowered to $20 from $24 at RBC Capital

RBC Capital lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $20 from $24 and keeps an Outperform rating on the shares after its Q4 results. The company also shared its first look at PKP2-ACM, and the firm is positive on safety as the drug has been generally well tolerated with no TEAE – Treatment emergent adverse events – which is key given a starting dose that is 40-times higher vs. the highest dose tested so far for Friedreich ataxia, the analyst tells investors in a research note.